News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Daily News For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7 Caitlin E. Cox October 23, 2023
News Daily News Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA Todd Neale September 19, 2023
News Daily News Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets Michael O'Riordan September 14, 2023
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ESOC 2023 ECST-2: No Benefit of Carotid Revascularization on Top of Best Medical Therapy Todd Neale May 26, 2023
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023